Table 4 of Liu, Mol Vis 2016; 22:352-361.


Table 4. Chemokines in patients with recurrent and treat-naïve wet AMD.

Chemokines
(pg/ml) recurrent AMD
(n=9) treat-naive AMD
(n=7) p*
IP-10/CXCL10 37.19±15.90 23.93±7.32 0.012
OPN 35,783±19576.33 46,400±28001.29 0.408
PARC/CCL18 1273.4±932.19 1593.5±1309.88 0.837
GRO 110.14±55.02 66.56±37.98 0.174
HCC-1/CCL14 317.84±91.22 310.79±55.08 0.918
CXCL16 1167.8±463.25 1076.1±547,57 0.837
ENA-78/CXCL5 32.49±25.01 51.22±11.30 0.113
LIGHT/TNFSF14 25.05±15.01 24.06±12.63 1
GCP-2/CXCL6 129.24±92.38 115.60±70.52 0.864
CCL28 124.93±45.56 132.41±25.68 0.918
NAP-2/CXCL7 15.92±7.10 18.71±6.33 0.47
HCC-4/CCL16 44.51±24.93 33.94±18.67 0.351
SDF-1/CXCL12 162.31±88.96 98.37±25.70 0.257
PF4 778.14±321.04 1020.3±780.25 0.95
MDC/CCL22 175.39±46.03 137.16±37.70 0.002